Table 4.

Antiviral prophylaxis and clinical outcomes of the included patients.

Patient	Antiviral prophylaxis	Clinical outcomes	Overall survival	Description of cause of death
1a	ADVc 10 mg/day	Died	10 months	The patient died of lymphoma recurrence, hepatic failure, hepatic encephalopathy and gastrointestinal bleeding, whereas the HBV DNA still remained negative.
2	ETVd 0.5 mg/day	Alive	80 months
3	ETV 0.5 mg/day	Alive	68 months
4	ETV 0.5 mg/day ADV 10 mg/day	Loss to follow-up	13 months	The patient was diagnosed as DLBCL in Nov. 2015, and the loss of follow-up occurred in Dec. 2016.
5b	ETV 0.5 mg/day	Alive	60 months
6b	ETV 0.5 mg/day	Died	7 months	The patient died of lymphoma progression, whereas the HBV DNA still remained negative.
7	ETV 0.5 mg/day	Died	18 months	The HBV reactivation occurred after the tumor progression in the patient, and finally he died of lymphoma progression.
8b	ETV 0.5 mg/day	Alive	82 months

^aCombined with hepatocellular carcinoma (HCC). ^bDecompensated cirrhosis. ^cADV, adefovir dipivoxil; ^dETV, entecavir.